Epidemiology of neonatal sepsis caused by multidrug resistant pathogens in a neonatal intensive care unit level 3

Med Glas (Zenica). 2020 Aug 1;17(2):375-382. doi: 10.17392/1157-20.

Abstract

Aim Steady progress in intensive treatment worldwide has increased the survival of immature neonates, but with multiple invasive procedures, which have increased the risk of infection, thus the bacterial resistance to antibiotics. The aim of this study was to analyse the epidemiology of multidrug resistance pathogens as causative agents of neonatal sepsis in the neonatal intensive care unit. Methods A retrospective cohort study conducted at the Intensive care unit of the Paediatric Clinic of Tuzla over a three-year period (2016-2018) analysed epidemiology of neonatal sepsis caused by multidrug resistance pathogens. Statistical analysis applied standard methods, and the research was approved by the Ethics Committee of the institution. Results Of the total of 921 treated neonates, multidrug resistance (MDR) pathogens among causative agents of neonatal sepsis were found in 22 neonates (2.38%) with no gender difference. Prematurity and low birth weight were confirmed as the most significant risk factors. From the maternal risk factors a significant difference was found in the first birth and in vitro fertilization. Clinically, MDR sepsis manifested frequently as late onset sepsis, with longer hospital stay and higher mortality. The findings of leukopenia, thrombocytopenia and coagulation disorders were significant. Gram negative bacteria were frequently isolated, in particular Acinetobacter, which showed the greatest resistance to antibiotics. Conclusion Neonatal MDR sepsis is a threat to life, it complicates the treatment, increases costs and mortality. Outcomes can be improved by preventive strategies, earlier and more accurate diagnosis and rational use of antibiotics.

Keywords: antibiotic resistance; incidence; intensive care; neonatal early onset sepsis; neonatal late onset sepsis.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Gram-Negative Bacteria
  • Humans
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Microbial Sensitivity Tests
  • Neonatal Sepsis* / drug therapy
  • Neonatal Sepsis* / epidemiology
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents